{"id":"NCT03221426","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","officialTitle":"A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-09","primaryCompletion":"2024-02-16","completion":"2025-04-23","firstPosted":"2017-07-18","resultsPosted":"2025-02-20","lastUpdate":"2025-07-14"},"enrollment":1007,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Placebo","otherNames":["Normal saline solution"]},{"type":"DRUG","name":"Cisplatin","otherNames":["PLATINOL®"]},{"type":"DRUG","name":"Capecitabine","otherNames":["XELODA®"]},{"type":"DRUG","name":"5-fluorouracil","otherNames":["ADRUCIL®","5FU"]},{"type":"DRUG","name":"Docetaxel","otherNames":["TAXOTERE®"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":["ELOXATIN®"]},{"type":"DRUG","name":"Leucovorin","otherNames":["WELLCOVORIN®"]}],"arms":[{"label":"Pembrolizumab + XP/FP","type":"EXPERIMENTAL"},{"label":"Placebo + XP/FP","type":"PLACEBO_COMPARATOR"},{"label":"Pembrolizumab+FLOT Cohort","type":"EXPERIMENTAL"},{"label":"Placebo+FLOT Cohort","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.\n\nThe primary study hypotheses are that:\n\n* Neoadjuvant and adjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab is superior to neoadjuvant and adjuvant placebo plus chemotherapy, followed by adjuvant placebo in terms of Event-free Survival (EFS) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), and\n* Neoadjuvant pembrolizumab plus chemotherapy is superior to neoadjuvant placebo plus chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.\n\nWith Amendment 10, upon study completion, participants will be discontinued and may be enrolled in an extension study.","primaryOutcome":{"measure":"Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms","timeFrame":"Up to approximately 75 months","effectByArm":[{"arm":"Pembrolizumab + XP/FP","deltaMin":44.4,"sd":null},{"arm":"Placebo + XP/FP","deltaMin":25.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.01501"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":171,"countries":["United States","Belgium","Brazil","Canada","Chile","China","Estonia","France","Germany","Guatemala","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Philippines","Poland","Russia","Singapore","South Korea","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["38134948","40829093","35623069","30777447"],"seeAlso":["http://merckclinicaltrials.com/","https://msd.trialsummaries.com/Study/StudyDetails?id=26112&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":176,"n":399},"commonTop":["Nausea","Diarrhoea","Decreased appetite","Anaemia","Neutrophil count decreased"]}}